BioSpace News Archive

Freenome demonstrates potential for patient stratification and monitoring using its multiomics platform at the American Association for Cancer Research (AACR) Annual Meeting

Xencor, Inc. announced the presentation of new data from multiple preclinical XmAb® bispecific antibody programs and its preclinical IL-12-Fc cytokine program at the American Association for Cancer Research Annual Meeting, being held virtually April 10-15, 2021.

Synthekine Inc., an engineered cytokine therapeutics company, announced preclinical data presented at the American Association of Cancer Research Annual Meeting 2021 demonstrating its alpha/beta selective IL-2 partial agonist, STK-012, induced potent anti-tumor activity while avoiding the toxicities that have hindered the development of IL-2 therapeutics, including vascular leak syndrome.

Phase 2 trial of Amgen’s investigational KRASG12C inhibitor, sotorasib, demonstrated comparable efficacy between patients identified as KRASG12C positive using Guardant360 CDx liquid biopsy or tissue biopsy

Phase 1/1b results for the etrumadenant combination demonstrated a 4.2 month PFS, approximately double the 2 months reported for current standard of care therapies in the ≥3L mCRC setting

Preclinical research included in poster supports clinical findings and demonstrates enhanced immune response in metastatic breast carcinoma model

Study demonstrates GMI-1757’s impact on immune cell infiltration and improvement of anti-PD-L1 therapeutic activity

Gracell Biotechnologies Inc. presented updated long-term follow-up data on their TruUCAR-enabled allogeneic product candidate GC027 for the treatment of adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia in an e-poster presentation at the 2021 American Association for Cancer Research Annual Meeting on April 10.

JBI-778, a brain penetrant PRMT5 inhibitor demonstrated significant tumor growth inhibition in glioblastoma in addition to its activity against a number of other cancers

CFT7455 Demonstrated High Cereblon Binding Affinity and Rapid, Deep IKZF1/3 Degradation Enabling Activity across a Panel of Multiple Myeloma Cell Lines Including IMiD-Resistant Models